Can I Take Vitamin B12 with Rezdiffra (Resmetirom)?

What Is Resmetirom and Why Does It Matter for Supplement Safety?

Resmetirom (brand name Rezdiffra, manufactured by Madrigal Pharmaceuticals) is the first FDA-approved pharmacotherapy for metabolic dysfunction-associated steatohepatitis, or MASH, previously called non-alcoholic steatohepatitis (NASH). The FDA granted approval in March 2024 for adults with non-cirrhotic MASH and stage F2 or F3 hepatic fibrosis [1]. Understanding its mechanism shapes how clinicians think about supplement co-administration.

Mechanism: Thyroid Receptor-Beta Selectivity

Resmetirom selectively activates thyroid hormone receptor-beta (THR-beta) in the liver. This selectivity reduces hepatic lipogenesis, lowers LDL-C, and improves liver histology without the cardiac or bone adverse effects linked to systemic thyroid hormone excess [2]. Because it targets a nuclear receptor that regulates gene transcription, its interaction profile differs substantially from cytochrome P450-heavy drugs.

The FDA label lists resmetirom as a substrate of CYP3A4, P-glycoprotein (P-gp), and OATP1B1/1B3 [1]. Vitamin B12 uses none of those pathways. B12 absorption depends on intrinsic factor in the stomach and active transport via the cubam receptor complex in the terminal ileum [3]. These are separate biological systems with no known convergence point.

Why MASH Patients Are a Distinct Population

MASH does not exist in isolation. Most patients carry metabolic comorbidities including type 2 diabetes, obesity, and dyslipidemia. In MAESTRO-NASH (N=966), roughly 45% of enrolled participants had type 2 diabetes at baseline [4]. A large proportion of those patients take metformin, and metformin is the most documented pharmaceutical cause of B12 depletion in clinical practice [5]. That overlap, not any direct resmetirom-B12 interaction, is the primary reason B12 status deserves attention in this population.

Is There a Pharmacokinetic Interaction Between Resmetirom and Vitamin B12?

No pharmacokinetic interaction between resmetirom and vitamin B12 has been reported in the published literature, the FDA label, or structured interaction databases. This conclusion rests on a straightforward mechanistic argument.

Absorption Pathways Do Not Overlap

Resmetirom reaches peak plasma concentration approximately 4 hours after oral dosing and is extensively protein-bound (greater than 99%) [1]. It is metabolized in the liver via CYP3A4 and glucuronidation, then excreted primarily in bile [1].

Vitamin B12 follows a completely different absorption sequence. Dietary B12 binds to haptocorrin in the stomach, transfers to intrinsic factor secreted by gastric parietal cells, and is absorbed in the distal ileum via cubilin-mediated endocytosis [3]. Once in the bloodstream, B12 binds to transcobalamin II for delivery to tissues [6]. None of these steps involve CYP3A4, P-gp, or OATP transporters.

Pharmacodynamic Independence

Resmetirom's pharmacodynamic target is THR-beta in hepatocytes. Vitamin B12 functions as a cofactor for methionine synthase (converting homocysteine to methionine) and methylmalonyl-CoA mutase (converting methylmalonyl-CoA to succinyl-CoA) [6]. These pathways operate independently. No evidence suggests that B12 alters THR-beta signaling, and resmetirom does not appear to affect cobalamin metabolism based on available trial data [4].

What the MAESTRO-NASH Trial Recorded

The MAESTRO-NASH phase 3 trial (N=966, 52 weeks) evaluated resmetirom 80 mg and 100 mg versus placebo in adults with biopsy-confirmed MASH [4]. The trial did not restrict concomitant supplement use, and no B12-related adverse events or signal emerged in the published safety data. At 52 weeks, 25.9% of patients in the 100 mg arm achieved NASH resolution versus 9.7% on placebo (P<0.001), and 24.2% achieved fibrosis improvement of at least one stage versus 14.2% on placebo (P<0.001) [4].

The Metformin-B12 Depletion Issue in MASH Patients

This is the core clinical concern for most people asking about B12 and Rezdiffra. Metformin reduces intestinal absorption of vitamin B12 by competing with the calcium-dependent uptake of the intrinsic factor-B12 complex at the ileal cubilin receptor [5].

Epidemiology of Metformin-Induced B12 Deficiency

A landmark study published in the Archives of Internal Medicine (N=155) found that 22% of metformin-treated patients developed biochemical B12 deficiency over a 4-year follow-up compared with 10% of controls [7]. The UKPDS extension data and a 2019 meta-analysis covering more than 7,500 patients confirmed that risk of B12 deficiency rises approximately 51% with metformin use, dose-dependently [8]. Given that nearly half of MAESTRO-NASH participants had type 2 diabetes, a meaningful fraction of Rezdiffra patients will be on metformin concurrently.

Clinical Consequences of Undetected B12 Deficiency

Low B12 causes megaloblastic anemia and, separately, subacute combined degeneration of the spinal cord resulting in peripheral neuropathy, proprioceptive loss, and cognitive changes [6]. Neuropathy from B12 deficiency can be difficult to distinguish from diabetic peripheral neuropathy, which is common in the same MASH population. Serum methylmalonic acid (MMA) and holotranscobalamin are more sensitive early markers than serum B12 alone [9].

The American Diabetes Association 2024 Standards of Care (section 9) state that "long-term metformin use is associated with vitamin B12 deficiency, and periodic measurement of vitamin B12 levels should be considered in metformin-treated patients, especially in those with anemia or peripheral neuropathy" [10].

Monitoring Protocol for Rezdiffra Patients on Metformin

Check serum B12 at baseline before starting resmetirom, particularly if the patient has been on metformin for more than 12 months. Recheck every 12 months. If serum B12 falls below 300 pg/mL, add oral cyanocobalamin 1,000 to 2,500 mcg daily or methylcobalamin 1,000 mcg daily. Intramuscular hydroxocobalamin 1,000 mcg monthly is appropriate for documented malabsorption or severe neurological symptoms [11].

Does Resmetirom's Thyroid Mechanism Affect B12 Metabolism?

Thyroid hormone influences gastric acid secretion and gastrointestinal motility, both of which can secondarily affect B12 absorption. Hypothyroid states reduce gastric acid output and slow transit, potentially impairing B12 release from food [12]. Resmetirom, however, acts selectively on THR-beta in the liver and does not produce systemic thyroid hormone-like effects on the gut. Serum TSH, free T4, and free T3 remain stable during resmetirom treatment based on MAESTRO-NASH endocrine substudy data [4].

No Evidence of Gut Motility Changes

Resmetirom's most common gastrointestinal adverse effects are nausea (26% for 100 mg vs. 16% placebo) and diarrhea (34% for 100 mg vs. 22% placebo) in MAESTRO-NASH [4]. These effects are modest and transient, typically resolving within the first 4 to 8 weeks. Transient loose stools do not meaningfully alter ileal B12 absorption in the absence of structural bowel disease [13].

Hepatic B12 Storage Considerations

The liver stores 1 to 5 mg of vitamin B12, enough to sustain normal function for 3 to 5 years in the absence of dietary intake [6]. Resmetirom reduces hepatic steatosis and improves liver cell function, which theoretically supports rather than impairs hepatic B12 storage. No mechanistic pathway exists by which THR-beta activation would reduce hepatic cobalamin reserves.

Which Forms of Vitamin B12 Are Appropriate?

Cyanocobalamin is the most studied and most cost-effective oral form. Methylcobalamin is the active cofactor form and requires no hepatic conversion step. Hydroxocobalamin is preferred for intramuscular repletion due to its longer half-life compared to cyanocobalamin IM [11].

Dose Guidance for Supplementation

For prevention in metformin-treated adults, 1,000 mcg oral cyanocobalamin daily maintains serum B12 within the normal range in most patients [7]. For repletion of established deficiency with serum B12 below 200 pg/mL, doses of 2,000 mcg oral daily achieve adequate absorption even in patients with reduced intrinsic factor because approximately 1% of oral B12 is absorbed by passive diffusion independent of intrinsic factor [11].

High-dose B12 supplements (above 5,000 mcg daily) are generally considered safe given the water-soluble, non-toxic profile of cobalamin, but doses in that range are rarely necessary for a MASH patient on resmetirom [6].

Timing Relative to Resmetirom Dosing

Because there is no pharmacokinetic interaction, no dose-separation window is needed. Patients may take their B12 supplement at any time relative to their once-daily resmetirom dose. Taking resmetirom with food reduces nausea per the FDA label [1], so morning administration with breakfast is common. A B12 supplement taken at the same time poses no concern.

What Other Supplements Should Be Discussed with Your Prescriber?

B12 is not the only supplement relevant to Rezdiffra patients.

Vitamin E

The American Association for the Study of Liver Diseases (AASLD) 2023 NAFLD/MASH Practice Guidance notes that vitamin E 800 IU/day may have modest histological benefit in non-diabetic MASH but raises concerns about all-cause mortality at very high doses and should be used under physician supervision [14]. Resmetirom and vitamin E do not share metabolic pathways, but both are being studied in MASH, and the combination has not been evaluated in controlled trials.

Omega-3 Fatty Acids

High-dose prescription omega-3s (icosapentaenoic acid, eicosapentaenoic acid) are sometimes prescribed alongside resmetirom for dyslipidemia management in MASH. No pharmacokinetic interaction with resmetirom has been identified [1]. Over-the-counter fish oil at standard doses (1 to 3 grams daily) does not raise concern.

Supplements Affecting CYP3A4

Because resmetirom is a CYP3A4 substrate, supplements that meaningfully inhibit CYP3A4 could raise resmetirom plasma levels. St. John's Wort is a potent CYP3A4 inducer and is listed as contraindicated with many CYP3A4-substrate drugs [15]. Grapefruit-derived supplements (bergamottin) can inhibit intestinal CYP3A4 [15]. Patients should avoid both while on resmetirom. Vitamin B12 has no effect on CYP3A4 activity.

Practical Clinical Guidance: B12 and Rezdiffra Together

The following is a summary decision framework for clinicians and patients.

Step 1. Assess metformin co-use. If the patient takes metformin concurrently with resmetirom, B12 monitoring is warranted regardless of symptoms.

Step 2. Check baseline serum B12. Obtain serum B12 (and MMA if borderline) before or within the first month of starting resmetirom. A normal adult reference range is 200 to 900 pg/mL, though values below 300 pg/mL may indicate subclinical deficiency in symptomatic patients [9].

Step 3. Supplement if indicated. Serum B12 below 300 pg/mL with concurrent metformin use warrants supplementation with 1,000 to 2,500 mcg oral cyanocobalamin daily. Neurological symptoms with any low-normal B12 level warrant IM repletion and neurology referral.

Step 4. Recheck annually. Serum B12 should be rechecked every 12 months in patients on ongoing metformin therapy, consistent with ADA 2024 guidance [10].

Step 5. No dose separation needed. Take B12 and resmetirom at whatever time fits daily routine. No interaction risk requires timing adjustments.

Step 6. Disclose all supplements. Patients should inform their prescribing clinician of all supplements, especially fat-soluble vitamins at high doses and herbal products, given resmetirom's CYP3A4 and P-gp substrate status.

Resmetirom and Liver Function: Why Hepatic Health Matters for B12

MASH itself damages hepatocytes. Severe liver disease impairs multiple metabolic functions including the hepatic storage and conversion of vitamin B12 [6]. Resmetirom's mechanism of action, reducing hepatic fat and inflammation, may over time restore some of this impaired hepatic function.

MAESTRO-NASH Histological Outcomes

In MAESTRO-NASH, 52 weeks of resmetirom 100 mg produced statistically significant improvements in liver steatosis grade, lobular inflammation, and hepatocyte ballooning compared with placebo [4]. Liver stiffness measured by MRE decreased by a mean of 1.3 kPa in the 100 mg group versus 0.3 kPa in placebo (P<0.001) [4]. As hepatic function normalizes, the liver's capacity to store and process B12 likely improves as well, though direct cobalamin storage data from MAESTRO-NASH have not been published.

Cirrhosis Exclusion and B12 Malabsorption

Resmetirom is currently approved only for non-cirrhotic MASH (F2-F3 fibrosis). Cirrhosis carries higher risk of B12 malabsorption due to reduced intrinsic factor secretion, portal hypertension, and gut dysbiosis [16]. Patients who progress to cirrhosis during or after resmetirom treatment may need reassessment of their B12 status and supplementation strategy.

Safety Profile of High-Dose Oral B12 in MASH Patients

Vitamin B12 is water-soluble with no established tolerable upper intake level (UL) from the Institute of Medicine, meaning no maximum safe dose has been set [6]. Excess B12 is excreted renally. Concerns about high-serum B12 as a cancer biomarker have been raised in observational data, but this reflects underlying disease causing B12 release from damaged tissues rather than supplementation causing cancer [17].

Renal Considerations

Resmetirom is not renally cleared to a significant degree, and B12 renal excretion does not interact with drug transporters relevant to resmetirom [1]. Patients with CKD stage 3 or above may accumulate methylmalonic acid independently of B12 intake, requiring careful interpretation of MMA levels [9].

Injection vs. Oral Route

A 2018 systematic review and meta-analysis in the British Journal of General Practice (10 RCTs, N=2,426) found that high-dose oral B12 (1,000 to 2,000 mcg daily) was as effective as intramuscular B12 for correcting deficiency in most patients, including some with pernicious anemia [18]. This supports the oral route as the first choice for MASH patients on resmetirom, reserving IM injection for documented malabsorption syndromes or severe neurological presentations.